NIH Commits $720K to Co-Fund Phase II Mesenchymal Stem Cell Trial for Moderate to Severe Lupus
核心洞察
The National Institute of Allergy and Infectious Diseases (NIAID) has committed $720,000 in first-year funding to co-sponsor a phase II study evaluating mesenchymal stem cells (搜索) (MSC) for moderate to severe lupus (搜索).
The five-year public-private partnership with the Lupus Foundation of America (搜索) builds on the Foundation's previously announced $3.8 million commitment, with NIAID also funding a data coordination center and mechanistic studies.
The US-based trial, expected to open for enrollment in summer 2018, aims to determine whether MSC therapy can serve as a safe, effective alternative for patients who do not benefit from current treatments.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has committed $720,000 in first-year funding to co-sponsor a major phase II clinical study evaluating mesenchymal stem cells (搜索) (MSC) as a treatment for moderate to severe lupus (搜索). The five-year commitment, announced by the Lupus Foundation of America (搜索) (LFA), establishes a new public-private partnership that will also see NIAID fund a data coordination center, site and safety monitoring, and mechanistic studies for the duration of the trial.
This federal investment adds to the Lupus Foundation of America (搜索)'s previously announced $3.8 million in funding over the five-year period, underscoring what the LFA describes as the growing importance of collaboration between government, non-profit, and research partners to advance lupus (搜索) research.
Addressing an Unmet Need in Lupus (搜索) Treatment
The phase II study represents what the LFA characterizes as an innovative step forward in lupus (搜索) research. According to the Foundation, the trial is the first step in determining whether stem cell therapy holds promise as a safe and effective alternative for people with lupus who do not benefit from currently available treatments.
The study also seeks to determine whether MSC stem cell therapy may diminish the often debilitating long-term effects of lupus (搜索), reduce the need for medications such as steroids (搜索)—which carry harmful side effects—and stop damage to vital organs. Lupus is a complex autoimmune disease that can affect nearly every organ in the body, including the kidneys, heart, lungs, brain, and skin, with symptoms that vary widely from person to person.
Trial Design and Timeline
The US-based mesenchymal stem cell clinical study is expected to open for enrollment in summer 2018. Under the partnership structure, NIAID's five-year commitment includes support for a data coordination center, site and safety monitoring, and mechanistic studies that will run alongside the clinical investigation.
The Case for Public-Private Partnership
Sandra C. Raymond, Chief Executive Officer of the Lupus Foundation of America (搜索), emphasized the critical nature of sustained research funding for the lupus (搜索) community. "Robust funding is vital to moving lupus research forward. Without sufficient funding from public and private resources, research treatments will be delayed, and the search for better treatments and cures will be seriously impaired," Raymond said.
She added: "People with lupus (搜索) need and deserve better treatment options now. This clinical study represents an innovative step forward in lupus research, and our hope is that we will be able to add stem cell therapy to the arsenal of treatments available for people with lupus."
The LFA noted that this collaboration is particularly important for lupus (搜索), a disease that the organization describes as greatly underfunded relative to its scope and devastation. Many patients currently struggle to find medications that control their disease without serious side effects, and the Foundation has consistently advocated for faster development of safer and more effective treatments through innovative clinical trials and precision medicine research.